^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BNT324

    i
    Company:
    BioNTech, DualityBio
    Drug class:
    Topoisomerase I inhibitor, B7-H3-targeted antibody-drug conjugate
    Related drugs:
    Apply
    A Study of DB-1311 in Advanced/Metastatic Solid Tumors (NCT05914116)
    Phase 1/2
    DualityBio Inc.
    Recruiting
    Last update posted :
    09/12/2023
    Initiation :
    09/05/2023
    Primary completion :
    04/01/2025
    Completion :
    04/01/2025
    EGFR • KRAS • BRAF • ALK • MET • ROS1 • NTRK1 • NTRK3 • NTRK2 • CD276
    |
    BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • BRAF V600 • NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ALK rearrangement • MET exon 14 mutation • ROS1 rearrangement • MET mutation • RET rearrangement • KRAS G12 • NTRK1 mutation • NTRK3 mutation
    |
    BNT324